Navigation Links
Molecular Breast Imaging Has Greater Sensitivity Over Mammography, Ultrasound and MRI for Invasive Lobular Carcinoma
Date:12/2/2008

CHICAGO, Dec. 2 /PRNewswire/ -- Breast-Specific Gamma Imaging (BSGI) has been proven to be a highly sensitive imaging technique for the diagnosis of invasive lobular carcinoma (ILC), a difficult to diagnose breast cancer. BSGI is a molecular breast imaging technique that can see lesions independent of tissue density and discover very early stage cancers. When compared to mammography, ultrasound and magnetic resonance imaging (MRI), BSGI has the greatest sensitivity for detecting ILC, according to findings presented today at the annual meeting of the Radiological Society of North America (RSNA).

"Our study compares the sensitivity of mammography, ultrasound, MRI and BSGI in the detection of ILC. We found BSGI to have the greatest sensitivity of all four techniques," said Dr. Rachel Brem, Director of Breast Imaging and Intervention at George Washington University Medical Center in Washington, D.C., and Vice Chair of the Department of Radiology.

This study was a retrospective multi-center study of women with biopsy-proven pure ILC. Patients had imaging performed with mammography and BSGI. Ultrasound and MRI results, if performed, and pathologic tumor size were included for analysis. The sensitivity of mammography, ultrasound, MRI and BSGI was determined for each modality and compared. Twenty-six women, ages 46 to 82 (mean age of 62.8), with 28 biopsy proven pure ILC, mean size of 22.3mm (2mm -90mm) were included.

BSGI had the greatest sensitivity for the detection of ILC with a sensitivity of 93 percent. Mammography, ultrasound and MRI demonstrated sensitivities of 79 percent, 68 percent and 83 percent, respectively.

The BSGI for the study was conducted using a Dilon 6800 Gamma Camera, a high-resolution, small field-of-view gamma camera, optimized to perform BSGI. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than the normal surrounding tissue and generally appear as "hot spots" on the BSGI image.

Dr. Brem has published many articles on breast cancer-related topics in her areas of interest, which include new technologies for the early diagnosis of breast cancer and BSGI.

"BSGI is an effective adjunct imaging modality for the diagnosis of breast cancer and has a promising role in the diagnosis of ILC," said Dr. Brem.

About Dilon Technologies

Dilon Technologies Inc. is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston.

For more information on Dilon Technologies please visit http://www.dilon.com.


'/>"/>
SOURCE Dilon Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. A new molecular zip code, and a new drug target for Huntingtons disease
2. New knock-out gene model provides molecular clues to breast cancer
3. Molecular probe paints cancer cells in living animals, Stanford researchers find
4. Story ideas from molecular & cellular proteomics
5. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
8. Molecular profiling can accurately predict survival in colon cancer patients
9. Xceed Molecular Names Fran Tuttle to Its Board of Trustees
10. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
11. Xceed Molecular Launches Ziplex(R) Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
(Date:6/24/2016)... ... ... recruitment firm Slone Partners is pleased to announce the placement of Suzanne ... of North American Capital Sales at HTG Molecular . , In ... commercialization of the HTG EdgeSeq system and associated reagents in North America. , Headquartered ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology: